Perspective Therapeutics Inc. (CATX) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Perspective Therapeutics Inc. (NYSE: CATX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.15 (-1.71% 1D, market cap $133.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CATX ranks #614 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CATX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SPRB (Spruce Biosciences Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $134.6M) and OGI (Organigram Global Inc.) posts a C grade (62/100 RQD, P/E N/A, ROIC —, cap $135.4M). Among the 5-stock peer group, CATX leads on earnings multiple (N/A) while CATX leads on capital efficiency (-35.0% ROIC).
Per CATX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000728387), Perspective Therapeutics Inc. generated $0 in revenue, -$103.1M in net income, and -$95.2M in free cash flow against $267.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 22.4 (OVERSOLD (<32))
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While CATX currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.57) and Max Pain ($1.21) forces dealer call-delta covering toward $6.47.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Perspective Therapeutics Inc. (CATX) slipped -1.71% to $1.15, trading at 2% of its 52-week range ($1.06 – $6.16). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Perspective Therapeutics Inc. (CATX) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Perspective Therapeutics Inc. (CATX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Perspective Therapeutics Inc. (CATX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Perspective Therapeutics Inc. (CATX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Perspective Therapeutics Inc. (CATX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Perspective Therapeutics Inc. (CATX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Perspective Therapeutics Inc. (CATX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Perspective Therapeutics Inc. (CATX) market action, institutional positioning, and fundamental catalysts.
RBC Capital analyst Leonid Timashev downgrades Perspective Therapeutics (AMEX:CATX) from Outperform to Sector Perform and lowers the price target from $14 to $4.
Perspective Therapeutics (NYSEAMERICAN:CATX) presented updated clinical data for its VMT-α-NET program at the European Society for Medical Oncology Congress 2026, reporting tumor responses, an 18-month progression-free s
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CATX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CATX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Perspective Therapeutics Inc. (CATX) ranks #614 by composite RQD confidence (37/100, grade D-) and #625 by equity capitalization ($133.6M). Within this direct 5-issuer industry benchmark cohort, CATX leads on earnings valuation at N/A trailing P/E, while CATX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OGI currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with CATX at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CATX
ACTIVE
Perspective Therapeutics Inc. | D- | 37/100 | — | — | -35.0% | -1.71% | $133.6M | Benchmark Subject |
| SPRB Spruce Biosciences Inc. | D- | 42/100 | — | — | -35.0% | -0.92% | $134.6M | /sprb-vs-catx → |
| OGI Organigram Global Inc. | C | 62/100 | — | — | — | -2.85% | $135.4M | /ogi-vs-catx → |
| KZIA Kazia Therapeutics Limited | C- | 61/100 | — | — | — | -2.52% | $135.6M | /kzia-vs-catx → |
| HURA TuHURA Biosciences Inc. | D- | 40/100 | — | — | -35.0% | -6.31% | $131.3M | /hura-vs-catx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Perspective Therapeutics Inc. (CATX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$103.1M, operating cash flow of -$82.5M, and free cash flow of -$95.2M (-31.0% YoY). On the balance sheet, CATX closed FY2025 with $267.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$103.1M | -$82.5M | -$95.2M | $267.0M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$79.3M | -$18.3M | -$72.7M | $341.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$46.5M | -$36.9M | -$36.9M | — | — |
As of 2026-11-02, Perspective Therapeutics Inc. (NYSE: CATX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.15 (-1.71% 1D, market cap $133.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CATX ranks #614 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CATX carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SPRB (Spruce Biosciences Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $134.6M) and OGI (Organigram Global Inc.) posts a C grade (62/100 RQD, P/E N/A, ROIC —, cap $135.4M). Among the 5-stock peer group, CATX leads on earnings multiple (N/A) while CATX leads on capital efficiency (-35.0% ROIC).
Per CATX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000728387), Perspective Therapeutics Inc. generated $0 in revenue, -$103.1M in net income, and -$95.2M in free cash flow against $267.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CATX last traded at $1.15 (-1.71% on volume of 2,309,354 shares), positioning the stock -55.25% below its 50-day simple moving average ($2.57) and -67.51% below its 200-day simple moving average ($3.54). Across its 52-week range of $1.06 to $6.16, CATX sits at the 1.8% percentile with a 14-day RSI of 22.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.01 to $1.29).
Why CATX Stock slipped -1.71% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
The Roarable RQD rating assigns a score of 37 out of 100, a letter grade of D-, and a verdict label of "Roarable Sell — Vulnerable Balance Sheet & Flow" (per the Roarable RQD rating). The score is built from five pillars, each weighted at 20 points:
Taken together, the rating points to a company with weak cash economics, limited institutional and insider endorsement, and a balance sheet that is serviceable but not strong on the forensic measures. The valuation tradeoff is that a low share price ($1.15 per market data) and a wide 52-week range ($1.06 - $6.16) can attract speculative interest, but the rating itself does not identify fundamental support for that interest. Prospective investors would need to weigh the score's emphasis on cash generation and flow against any upside thesis they hold, recognizing that catalyst-driven moves are not captured as durable value in the rating.
Perspective Therapeutics Inc. is a NYSE-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry (per the company profile). The profile reports a market capitalization of $0.1B. The source data does not describe specific products, customers, or revenue-generating activities. Revenue is reported as $0.0M across the available periods (per the SEC financials), indicating no reported revenue in the source data.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-113.6M | $-103.1M | N/A | $-95.2M | $30.6M | N/A |
| FY 2024 | $0.0M | $-90.9M | $-79.3M | N/A | $-72.7M | $61.6M | N/A |
| FY 2023 | $0.0M | $-40.9M | $-46.5M | N/A | $-36.9M | N/A | N/A |
Per the SEC financials, the company reported operating and net losses in every period shown, with operating losses widening from $-40.9M in FY 2023 to $-113.6M in FY 2025, and free cash flow remaining negative throughout. Gross, operating, and net margins are each reported as 0% (per the market data), and ROIC is -35% (per market data). Cash declined from $61.6M in FY 2024 to $30.6M in FY 2025 (per the SEC financials). The Altman Z-Score of 2.5, Piotroski F-Score of 2/9, and Debt/Equity of 0.5 are reported in the Roarable RQD rating. Debt values are not available in source data.
Per the Butterfly Supply-Chain Graph, the supply chain is reported as NONE, with no butterfly links and no proprietary signals. No upstream or downstream dependencies, sector correlation mappings, or 2nd-order bottlenecks are available in the source data. The sector assignment (Health Care; Biotechnology: Pharmaceutical Preparations) is the only structural context provided. Investors should note that the absence of mapped supply-chain links means ripple effects from suppliers, partners, or competitors cannot be assessed from the provided data.
Per the analyst data section, no analyst consensus, price targets, or rating aggregates are available. Individual firm actions appear only in the news feed: Wedbush (buy), BTIG (buy, $14 price target), and RBC (downgrade to Sector Perform, $4 price target) (per the recent news and catalysts section). Holder data is not available in source data: no SEC Form 4 insider, 13F institutional, or Congressional trade records are provided in the holders section.
Real-time company headlines, analyst actions, and sector developments for Perspective Therapeutics Inc. (CATX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Perspective Therapeutics Inc. (CATX) market action, institutional positioning, and fundamental catalysts.
The Globe and Mail report covering Perspective Therapeutics Inc. (CATX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Perspective Therapeutics Inc. (CATX) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Perspective Therapeutics Inc. (CATX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Perspective Therapeutics Inc. (CATX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Perspective Therapeutics Inc. (CATX) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Perspective Therapeutics Inc. (CATX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Perspective Therapeutics Inc. (CATX) market action, institutional positioning, and fundamental catalysts.
Welcome to the CATX (Perspective Therapeutics Inc.) Roar Pit. Current RQD Composite is 37/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on CATX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Perspective Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on CATX, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.15 (52-wk range $1.06 - $6.16), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).